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Abstract
4-Hydroxytamoxifen (OHTAM) is the most active metabolite of the widely prescribed anticancer drug tamoxifen (TAM) used in
breast cancer therapy. This work describes the effects of OHTAM on isolated human erythrocytes, using standardized test condi-
tions, to check for a putative contribution to the TAM-induced hemolysis and to study basic mechanisms involved in the interac-
tion of OHTAM with cell membranes. Incubation of isolated human erythrocytes with relatively high concentrations of OHTAM
results in a concentration-dependent hemolysis, its hemolytic effect being about one-third of that induced by TAM. OHTAM-
induced hemolysis is prevented by either a-tocopherol (a-T) or a-tocopherol acetate (a-TAc) and it occurs in the absence of oxygen
consumption and hemoglobin oxidation, ruling out the oxidative damage of erythrocytes. However, OHTAM remarkably increases
the osmotic fragility of erythrocytes, increasing the susceptibility of erythrocytes to hypotonic lysis. Additionally, the hemoglobin
release induced by OHTAM is preceded by a rapid efflux of intracellular K+. Therefore, our data suggest that OHTAM-induced
hemolysis does not contribute to TAM-induced hemolytic anemia and it is a much weaker toxic drug as compared with TAM.
Moreover, at variance with the membrane disrupting effects of TAM, OHTAM promotes perturbation of the membrane’s back-
bone region due to its strong binding to proteins with consequent formation of membrane paths of permeability to small solutes
and retention of large solutes like hemoglobin, followed by osmotic swelling and cell lysis. The prevention of OHTAM-induced
hemolysis by a-T and a-TAc is probably committed to the permeability sealing resulting from structural stabilization of membrane.
# 2001 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Tamoxifen (TAM) is a triphenylethylenic anti-estro-
gen commonly prescribed in the breast cancer therapy
(Jordan, 1990) and potentially useful in the prevention
of this malignant process (Nayfield et al., 1991).
Most studies indicated that the anticancer action of
TAM is not solely mediated by the antagonism at the
estrogen receptors (ER). Among the several mechan-
isms proposed, the interaction with biomembranes has
been favoured (Koedijk et al., 1994). In fact, TAM that
binds to proteins in a unspecific way (Oosbree et al.,
1984) partitions in a greater extent in native membranes
relatively to the respective lipid dispersions (Custo´dio et
al., 1991), where it interacts with lipids (Custo´dio et al.,
1993a) and proteins (Lopes et al., 1990; Custo´dio et al.,
1996), explaining the modifications in the morphology
and structure of breast tumor cell membranes (Sica et
al., 1984). Moreover, TAM disrupts model (Vogel et al.,
1995; Custo´dio et al., 1996) and mitochondrial mem-
branes (Custo´dio et al., 1998) and its hemolytic effect in
isolated human erythrocytes has been assigned to a
structural perturbation of the membrane integrity
caused by its strong accumulation within membranes
(Cruz-Silva et al., 2000). Therefore, the TAM-induced
structural disruption of biomembranes, as observed in
different membrane systems, may contribute for its ER-
independent anticancer activity and adverse effects,
including hemolytic anemia (Ching et al., 1992; Than-
garaju et al., 1995).
The metabolites of TAM transformation, mostly 4-
hydroxytamoxifen (OHTAM), have been reported to be
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pharmacologically active (Kemp et al., 1983), playing
an important role in the therapeutic activity and side-
effects of TAM (Jordan, 1990). Actually, the anti-estro-
genic and antiproliferative activities of OHTAM in vitro
are much stronger as compared with TAM (Borgna and
Rochefort, 1981; Etienne et al., 1989), but the pharma-
cological relevance of OHTAM has been questioned
(McCague et al., 1990) due to its low serum concentra-
tions (Lien et al., 1987; MacCallum et al., 1996). How-
ever, the strong affinity of OHTAM for biomembrane
proteins (Custo´dio et al., 1991) and its higher partition-
ing in the lipid bilayer as compared with TAM (Custo´-
dio et al., 1991), perturbing the membrane lipid-protein
interface (Custo´dio et al., 1993b) suggest that OHTAM
may accumulate in tissues, reaching there the required
effective concentrations for its cytotoxic effects, as
described by Lien et al. (1991).
Therefore, the reports of hemolytic anemia caused by
TAM (Ching et al., 1992; Thangaraju et al., 1995), the
strong incorporation of OHTAM into biomembranes
(Custo´dio et al., 1991) and the putative role of OHTAM
in the multiple cellular effects of TAM (Jordan, 1990)
prompted us to search for the effects of OHTAM on
isolated erythrocytes, attempting to clarify the con-
tribution of OHTAM to the hemolytic anemia caused
by TAM and the basic mechanisms underlying the
interaction of this metabolite with biomembranes. The
use of standardized methods is helpful to compare the
effects of OHTAM with data previously published
(Cruz-Silva et al., 2000).
2. Materials and methods
2.1. Chemicals
4-Hydroxytamoxifen, tamoxifen and a-tocopherol
acetate (a-TAc) were purchased from Sigma Chemical
Co (St Louis, MO, USA). 2,20-Azobis(2-amidinoprop-
ane)dihydrochloride (AAPH) was obtained from Poly-
sciences, Inc. (Warrington, PA, USA) and a-tocopherol
(a-T) from Fluka BioChemika (Switzerland). All the
other chemicals were of research grade. Solutions were
prepared in deionized ultra-pure water.
2.2. Red blood cells preparation
Heparinised human blood samples were centrifuged
at 3000 rpm for 10 min. The sediment of erythrocytes
was washed three times with 6 volumes of isotonic
phosphate buffered saline (PBS) (150 mm NaCl, 10 mm
sodium phosphate, pH 7.4) and the buffy coat was
removed with each wash, according to previous reports
(Urano et al., 1992; Dwight and Hendry, 1996; Koga et
al., 1998). The retrieved cells were resuspended in PBS
and the hematocrit determined. All the erythrocyte sus-
pensions used were prepared daily from freshly collected
blood obtained from 12 healthy donors (25–50 years old
and not submitted to any drug treatment) who are
working in our laboratory, as described elsewhere
(Cruz-Silva et al., 2000).
2.3. Hemolysis measurements
The hemolysis studies were performed in erythrocyte
suspensions (4 ml) in PBS with the hematocrit at 0.33%.
OHTAM or TAM were added from stock ethanolic
solutions (2–4 ml) to the erythrocyte suspensions and
incubated at 37 C in a shaking water-bath with mag-
netic stirring. The effects of a-T and a-TAc were asses-
sed by pre-incubating the erythrocyte suspensions with
these compounds at 37 C for 2 h, before the drug
addition. A set of samples, after the pre-incubation
period with the tocopherols, were washed three times
with 10 ml of PBS before the addition of OHTAM.
After the incubation periods, the erythrocyte suspen-
sions were centrifuged at 3000 rpm for 10 min and the
hemolysis degree was estimated by visible spectroscopy
at 540 nm from the hemoglobin released into the
supernatant, as described elsewhere (Koga et al., 1998).
The results were expressed as percent hemolysis. The
absorbance of the supernatant in the absence of
OHTAM was taken as zero hemolysis and the total
hemolysis (100%) was assigned when PBS was replaced
by water containing identical volume of ethanol as used
in the assays with OHTAM.
The osmotic fragility experiments were carried out
according to standardized procedures (Takeuchi et al.,
1989; Jackson et al., 1996) in phosphate buffered solu-
tions (10 mm sodium phosphate, pH 7.4) with increasing
concentrations of NaCl and a hematocrit of 0.33%.
After centrifugation at 3000 rpm for 10 min, the absor-
bance of supernatants was read at 540 nm.
The K+ leakage from erythrocytes was monitored
with a K+ ion-selective electrode. The total amount of
K+ was measured after the addition of 0.5% Triton X-
100 to the erythrocyte suspensions.
2.4. Erythrocytes oxidation measurements
The erythrocyte hemolysis induced by OHTAM were
followed by oxygen consumption and changes in hemo-
globin absorption spectrum, as described elsewhere
(Cruz-Silva et al., 2000).
The rate of oxygen consumption was measured with a
Clark-type oxygen electrode (YSI model 5331, Yellow
Spring Inst.), as previously described (Custo´dio et al.,
1994). The reactions were carried out at 37 C in a
closed glass vessel with magnetic stirring and the hemo-
lysis of erythrocyte suspension (hematocrit of 0.33%)
was induced by addition of 35 mm OHTAM. After 90
min of OHTAM incubation, the free radicals generator
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AAPH (20 mm) was added and oxygen consumption
was followed for another period of 60 min. The oxygen
consumption was calculated assuming that the O2 con-
centration in water was 177 nmol/ml at 37 C.
In the course of incubation of erythrocyte suspensions
with OHTAM and after addition of 20 mm AAPH, ali-
quots of the suspension were withdrawn, centrifuged at
3000 rpm for 5 min and the spectrum of the released
hemoglobin was recorded. The withdrawn aliquots were
chilled prior to centrifugation to stop the thermal decom-
position reaction of the azoinitiator. Hemoglobin oxida-
tion was followed by the decay of the absorption spectrum
in the range 450–650 nm, using a Perkin–Elmer Lambda 6
UV/VIS spectrophotometer (Norwalk, USA).
The results are typical assays or represent the mean
S.D. of three independent experiments.
3. Results
3.1. OHTAM-induced hemolysis
The effects of OHTAM in isolated human ery-
throcytes were assayed as a function of incubation time
and drug concentration in erythrocyte suspensions from
different human donors (Fig. 1, lines 1–4). This figure
shows the time-dependent hemolysis induced by 30 mm
OHTAM. Variations are observed in the susceptibility
of samples to hemolysis depending on the blood donor,
but an almost complete hemolysis is observed for all
samples with 30 mm OHTAM after 90 min of incuba-
tion, whereas 35 mm OHTAM induces full hemolysis
after this incubation time. As previously reported for
TAM (Cruz-Silva et al., 2000), the sensitivity of ery-
throcytes to hemolysis induced by OHTAM is also
lower for older subjects (Fig. 1, lines 3–4), according to
earlier reports pointing out that the hemolysis extension
decreases as a function of age as a consequence of
increased membrane cholesterol (Araki and Rifkind,
1980). As OHTAM partitioning in biomembranes
decreases as a function of cholesterol (Custodio et al.,
1991), the different effects induced by OHTAM in
diverse erythrocyte suspensions could be explained by
the putative protection ascribed to membrane choles-
terol. The hemolytic effect of OHTAM is also con-
centration dependent and total hemolysis is detected in
all the erythrocyte samples when incubated with 35 mm
OHTAM, at 37 C, for 90 min (Fig. 2).
The hemolytic action of OHTAM was also compared
with the effects of TAM in the same erythrocyte samples,
as shown in Fig. 2. TAM (12.5 mm) induces complete
hemolysis after 1 h of incubation, whereas the same
concentration of OHTAM does not promote any sig-
nificant effect and a total hemolysis is only achieved at
35 mm OHTAM after 1.5 h of incubation. Identical
experiments carried out with both drugs at 37 C for 1 h
demonstrated that 12.5 mm TAM induces total hemo-
lysis whereas 35 mm OHTAM promotes only about 70%
hemolysis (data not shown). The combination of low
concentrations of TAM (<7.5 mm) with OHTAM (<10
mm) does not change the effects observed with TAM
alone, meaning that in vivo the interaction between
these drugs will not cause increased hemolysis, in addi-
tion to the effect of TAM. Moreover, as described to
TAM (Cruz-Silva et al., 2000), OHTAM induces the
release of hemoglobin bound to the membrane, as eval-
uated by SDS–polyacrylamide gel electrophoresis,
explaining the extra absorbance as compared to the total
hemolysis induced by water (Fig. 2), also meaning that
OHTAM changes the binding of cytosol and cytoskele-
ton proteins to band 3, the most abundant intrinsic
protein of erythrocytes (Schuck and Schubert, 1991).
To clarify the potential mechanisms involved in the
hemolytic effect of high concentrations of OHTAM,
namely cellular oxidative stress or membrane structural
perturbations, the protective effects of antioxidants and
membrane stabilizers, for example a-T and a-TAc, were
studied.
OHTAM-induced hemolysis is partially prevented by
a-T (Fig. 3A) or a-TAc (Fig. 3B) previously incubated
with erythrocyte suspensions. When erythrocytes are
washed after the pre-incubation period to avoid the
interference of non-incorporated tocopherol compounds,
Fig. 1. OHTAM-induced hemolysis in human erythrocytes obtained
from different donors (lines 1–4). Erythrocyte suspensions in phos-
phate buffer saline (PBS) (0.33% hematocrit) were incubated with 30
mm OHTAM at 37 C, as a function of time. After incubation with the
drug, erythrocyte suspensions were centrifuged at 3000 rpm for 10 min
and hemolysis was estimated from the 540 nm absorbance of hemo-
globin released into the supernatant. Data are expressed as percentage
of total hemolysis induced by replacing the PBS by identical volume of
water.
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the protection against OHTAM-induced hemolysis is
nearly maintained as in unwashed erythrocytes
(Fig. 3A,B). Therefore, these protective effects puta-
tively result from the interaction of tocopherols with the
erythrocyte membrane core (Shinitzky and Barenholz,
1978), in agreement with the hydrophobicity, the high
membrane partition and ordering effects of these com-
pounds in lipid bilayer (Micol et al., 1990; Fukuzawa et
al., 1992; Cruz-Silva et al., 2000), indicating that
OHTAM-induced hemolysis is related with membrane
interaction. Moreover, the fact that a-TAc (with an
inactivated functional hydroxyl and deprived of anti-
oxidant activity) (Urano et al., 1992) inhibits also the
hemolytic process suggests that the free hydroxyl group
of a-T is not critical for protection against OHTAM-
induced damage and that the hemolysis will be not
caused by oxidative disruption of erythrocyte.
3.2. Effect of OHTAM on oxidative stress of
erythrocytes
To exclude the putative involvement of peroxidative
degradation mechanisms on the hemolytic effect of
OHTAM, the oxygen consumption and hemoglobin
oxidation were evaluated simultaneously in the same
erythrocyte suspension during the time course of the
drug-induced hemolysis. The hemolytic effect promoted
by 35 mm OHTAM, as followed by the increase in the
hemoglobin released to the supernatant, is not accom-
panied by a significant decrease in O2 concentration in
the medium (Fig. 4A) or changes in the spectra of the
released oxyhemoglobin (Fig. 4B), in contrast to the
abrupt O2 consumption (Fig. 4A) and conversion of the
typical spectra of oxyhemoglobin into methemoglobin
(Fig. 4C) induced by 20 mm AAPH, revealing an exten-
sive peroxidation of lipids and proteins induced by the
AAPH-derived radicals, as previously reported (Miki et
al., 1987; Sato et al., 1995). Therefore, an oxidative
Fig. 3. Protection of a-T (A) and a-TAc (B) against OHTAM-induced hemolysis. The erythrocyte suspensions in PBS (0.33% hematocrit) were pre-
incubated with the tocopherols at 37 C for 2 h and afterwards the erythrocytes were washed (*) or not (*) prior to the addition of 35 mm
OHTAM, followed by incubation at 37 C for 90 min. The hemolysis extension was estimated by the absorbance of supernatant at 540 nm as
described in the legend to Fig. 1. Each point represents the mean S.D. of three independent experiments.
Fig. 2. Comparison of the hemolytic effects induced by TAM (*) and
OHTAM (*) in the same erythrocyte suspension, as a function of drug
concentration. Erythrocyte suspension in PBS (0.33% hematocrit)
were incubated with different concentrations of either TAM at 37 C
for 1 h or OHTAM at 37 C for 1.5 h, and the hemolysis was calcu-
lated from the absorbance of supernatants at 540 nm after centrifuga-
tion of erythrocyte suspension. The recordings obtained from the
results expressed as percentage of total hemolysis are typical of three
independent experiments.
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challenge of erythrocytes by the presence of OHTAM is
not observed as compared with AAPH, a well-known
reference oxidant (Miki et al., 1987; Niki, 1990; Sato et
al., 1995). Moreover, the peroxidation process induced
by AAPH-derived peroxyl radicals in erythrocyte sus-
pensions, previously lysed with hypotonic PBS, is sig-
nificantly inhibited by OHTAM, as assessed by O2
consumption (results not shown), pointing to the anti-
oxidant activity of OHTAM in this biological system, as
previously reported in other studies regarding the anti-
oxidant mechanisms of OHTAM (Custo´dio et al., 1994;
Wei et al., 1998).
3.3. Osmotic behavior of erythrocytes in the presence of
OHTAM
The hemolytic action dependent on putative mem-
brane perturbations was evaluated by the hemolytic
fragility analysis as a function of NaCl concentration
(Fig. 5). Incubation of the erythrocyte suspensions with
10 mm OHTAM does not change the osmotic fragility
profile, as compared to the control conditions. How-
ever, 20 mm OHTAM, with no significant hemolytic
effect in isotonic medium, considerably shifts the fragi-
lity profile. As already observed before, 35 mm OHTAM
induces total hemolysis independently of the osmolarity
(data not shown). In contrast to TAM (Cruz-Silva et al.,
2000), OHTAM increases the susceptibility of ery-
throcytes to hypotonic lysis, through changes in mem-
brane permeability.
To further explore this permeabilizing effect, the efflux
of intracellular K+ in parallel with hemoglobin release
was searched, since K+ efflux has revealed a reliable
methodology for the assay of permeability changes
induced by several hemolytic compounds (Cybulska et
al., 1995; Jackson et al., 1996).
Fig. 6 displays the K+ and hemoglobin leakage curves
resulting from the incubation of erythrocyte suspensions
with 35 mm OHTAM at 25 C. Release of about 60% of
intracellular K+ occurs in a short period (2 min) and the
remaining K+ is gradually released after 20 min of
incubation. In contrast, the release of hemoglobin to the
Fig. 4. Oxygen consumption rates (—) associated with hemolysis of erythrocytes (*) incubated with 35 mm OHTAM and afterwards with 20 mm
AAPH (A) and spectra of hemoglobin after the addition of OHTAM (B) and AAPH (C). O2 consumption (A) and hemoglobin spectra were mon-
itored simultaneously during incubation of erythrocyte suspensions in PBS (0.33% hematocrit) with OHTAM at 37 C for 1.5 h (B) and after AAPH
addition (C), as described in Materials and Methods. Hemoglobin spectra were recorded at different reaction times indicated by the numbers adja-
cent to the traces. Upward and downward arrows indicate increase or decrease in absorbance due to hemoglobin release (B) and hemoglobin oxi-
dation by AAPH added 1.5 h after OHTAM (C). The results are representative of three different assays.
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extracellular medium is a late phenomenon and total
hemolysis is observed only after 90 min (Fig. 6). There-
fore, OHTAM induces the early formation of perme-
ability paths in the erythrocyte membrane, allowing the
rapid efflux of K+ prior to a large scale disruption of
the membrane, which permits the release of hemoglo-
bin.
4. Discussion
OHTAM interacts with human erythrocytes in vitro
in a different way from that recently described for TAM
(Cruz-Silva et al., 2000). The extension of OHTAM
hemolytic effects depends on blood donor, being lower
for older subjects (Fig. 1) as observed for TAM (Cruz-
Silva et al., 2000). However, a complete hemolysis
occurs only at 35 mm OHTAM, incubated at 37 C for
1.5 h, independently of the erythrocyte donor, whereas
12.5 mm TAM incubated at 37 C for 1 h induces total
hemolysis of erythrocytes (Fig. 2). Therefore, OHTAM
requires a threefold higher concentration to induce the
same hemolytic effect observed for TAM and the
hemolysis takes longer, pointing out that OHTAM
shows a much weaker hemolytic action than TAM.
Considering that the tissue and serum concentrations of
OHTAM are much lower as compared with TAM (Lien
et al., 1987, 1991; MacCallum et al., 1996), OHTAM
may not reach concentrations high enough to cause
hemolysis, suggesting that this drug does not contribute
to TAM-induced hemolytic anemia.
The inhibition of OHTAM-induced hemolysis by a-T
(Fig. 3A) could insinuate the oxidative damage of ery-
throcyte membrane as the mechanism involved in the
hemolytic effect, since a-T has a remarkable antioxidant
capacity, interrupting free radical chain reactions in
several membrane systems (Yamamoto and Niki, 1988;
Ernster, 1993), including the human erythrocyte mem-
brane (Yamamoto et al., 1985; Miki et al., 1987). How-
ever, a-TAc, with its chromanol hydroxyl group
acylated and thus deprived of antioxidant activity, also
suppresses that hemolytic effect (Fig. 3B). Additionally,
the hemolytic effect of OHTAM does not involve an
increase in the membrane peroxidation or hemoglobin
oxidative degradation (Fig. 4). On the other hand,
OHTAM protects the peroxidative degradation of ery-
throcyte components induced by peroxyl radicals,
according to its antioxidant properties in vitro (Custo´-
dio et al., 1994; Wei et al., 1998) and in vivo (Wei et al.,
1998), acting as a potent intramembraneous scavenger
of peroxyl radicals (Custo´dio et al., 1994). Therefore,
OHTAM-induced hemolysis is not caused by the oxi-
dative injury of the erythrocytes.
The effects of OHTAM on osmotic fragility and K+
release from erythrocytes are considerably different
from those described for TAM (Cruz-Silva et al., 2000),
and suggest different mechanisms of interaction with the
erythrocyte membrane. TAM does not change the
osmotic fragility curves of erythrocytes and shows only
a weak prelytic release of K+ from the cells (Cruz-Silva
et al., 2000), whereas OHTAM strongly shifts the
osmotic fragility profile and makes the red blood cells
leaky to K+ preceding the slower hemolysis process
(Fig. 6), supporting the conclusion that OHTAM-
Fig. 5. Osmotic fragility curves of human erythrocytes as affected by
the addition of OHTAM. The erythrocyte suspensions (0.33% hema-
tocrit) in a 10 mm phosphate buffer, pH 7.4, containing increasing
concentrations of NaCl were incubated at 37 C for 1.5 h in the
absence (*) and in the presence of 10 (*) and 20 mm OHTAM (&).
Hemolysis was estimated and expressed as described in the legend to
the Fig. 1.
Fig. 6. Time courses of K+ (—) and hemoglobin (---) release from
human erythrocytes in 150 mm NaCl, 10 mm sodium phosphate,
pH=7.4 (0.33% hematocrit) incubated with 35 mm OHTAM at 25 C.
The release of K+ was estimated with a K+ ion-sensitive electrode and
hemolysis was evaluated by spectrophotometry of the supernatant at
540 nm. The results are expressed as the percentage of total release in
complete hemolysis and are typical of several independent assays.
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induced hemolysis occurs via an osmotic swelling. In
fact, the osmotic hemolysis described for several com-
pounds (Lieber et al., 1984; Deuticke et al., 1989; Jack-
son et al., 1996) involves the formation of permeability
paths for small ions, which allow water osmosis as con-
sequence of the increased osmotic pressure inside the
erythrocyte. The osmotic imbalance causes cells to
swell, inducing physical rupture of the membrane fol-
lowed by hemoglobin leakage. OHTAM strongly parti-
tions in biomembranes (Custo´dio et al., 1991) and
distributes in the outer region of the lipid bilayer,
mainly in the lipid–protein interfaces (Custo´dio et al.,
1993b), which may account for membrane structural
perturbations reflected in the permeability status (Figs. 5
and 6). The inhibitory effects of a-T and a-TAc towards
OHTAM-induced hemolysis (Fig. 3) reflect a decrease of
the permeability (Urano et al., 1992) or the exclusion of
OHTAM from the membrane; that is, withdrawing the
drug from the interaction with membrane components
involved in the control of permeability due to the mem-
brane stabilization induced by both tocopherols (Micol et
al., 1990; Fukuzawa et al., 1992; Cruz-Silva et al., 2000).
In conclusion, OHTAM induces hemolysis, but to a
much smaller extent as compared with TAM, ruling out
this hemolytic effect in TAM-induced hemolytic anemia.
Moreover, our findings suggest that, differently from
those described for TAM (Cruz-Silva et al., 2000),
OHTAM induces permeabilization of the erythrocyte
membrane and a subsequent time-dependent hemolytic
process, via an osmotic mechanism, occurring at relatively
high concentrations. It is difficult to calculate precisely
the concentrations of OHTAM resulting from pharmaco-
logical doses of TAM due to its high hydrophobic char-
acter, partitioning in biological membranes (Custo´dio et
al., 1991) and high affinity to receptors in various target
tissues (Borgna and Rochefort, 1980, 1981), which in
humans is 10–60-fold higher in tissues than in serum
(Lien et al., 1991). However, the concentrations of
OHTAM that induce hemolysis (>25 mm) are not easily
reached in vivo in tissues and plasma, suggesting that
little or no toxicity is expected with OHTAM doses as
compared with TAM.
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